Primary anaplastic pleomorphic xanthoastrocytoma in adults.
Case report and review of literature

Usama Khalid Choudry
Aga Khan University

Saad Akhtar Khan
Aga Khan University

Amjad Qureshi
Aga Khan University, amjad.qureshi@aku.edu

Muhammad Ehsan Bari
Aga Khan University, ehsan.bari@aku.edu

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_neurosurg

Part of the Neurology Commons, Neurosurgery Commons, and the Surgery Commons

Recommended Citation
Choudry, U., Khan, S., Qureshi, A., Bari, M. (2016). Primary anaplastic pleomorphic xanthoastrocytoma in adults. Case report and review of literature. International Journal of Surgery Case Reports, 27, 183-188. Available at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_neurosurg/89
Primary anaplastic pleomorphic xanithoastrocytoma in adults. Case report and review of literature

Dr. Usama Khalid Choudry (Intern)\textsuperscript{b,∗}, Dr. Saad Akhtar Khan (Chief Resident)\textsuperscript{a}, Dr. Amjad Qureshi (Resident)\textsuperscript{a}, Dr. Ehsan Bari (Section Head)\textsuperscript{a,∗}

\textsuperscript{a} Department of Neurosurgery, Aga Khan University Hospital, Karachi, Pakistan
\textsuperscript{b} Department of Post Graduate Education, Aga Khan University Hospital, Karachi, Pakistan

\begin{abstract}
\textbf{BACKGROUND:} Pleomorphic xanithoastrocytoma (PXA) classified as a low Grade (WHO II) astrocytic neoplasm. It is known for its relatively favorable prognosis. It most commonly occurs in young adults. Malignant progression in PXA has been frequently reported since its first description in 1979; however, the presentation of a primary anaplastic PXA tumor with an aggressive clinical course in adults is rare especially in the later age group.

\textbf{CASE DESCRIPTION:} We present a case of primary anaplastic PXA in a 53 year old male that manifested with an early recurrence pattern at 9 weeks. Treatment performed was surgical excision and external beam radiotherapy. The aforementioned tumor followed an aggressive clinical course. Tumor cells exhibited the characteristic expression of GFAP (Glial fibrillary acidic protein), higher proliferative index (8–10%) on Ki-67 staining along with the presence of increased mitoses (>5/10hpf). A review of previously reported primary anaplastic pleomorphic xanithoastrocytoma cases in adults with histological features was also done.

\textbf{CONCLUSION:} Our review of all reported cases of APXA in adults concludes that the clinical behavior of this tumor varies considerably from its benign variant. Early disease recurrence in anaplastic pleomorphic xanithoastrocytomas is associated with fatal outcomes. As per our review of literature it is seen that anaplastic variant of PXA shows histological characteristics as well as clinical course comparable with Grade III astrocytomas.

We recommend further evaluation of PXA with anaplastic features regarding their genetic characteristics to understand the origin as well as behavior of this tumor.

© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
\end{abstract}

1. Introduction

Pleomorphic xanithoastrocytoma (PXA) is an astrocytic neoplasm with a relatively favorable prognosis [8]. According to WHO classification for astrocytic neoplasms, it has been classified histologically as a grade II (benign) neoplasm [6]. The first case was reported in 1979 [11]. It is often superficially located in the cerebral cortex with leptomeningeal involvement. Morphologically it shows a pleomorphic histological appearance that includes lipidized, GFAP-expressing tumor cells with cytoplasmic xanthic change surrounded by a reticulin network [9]. It has been frequently seen that tumors initially diagnosed as PXA have later shown malignant progression to high grade astrocytomas (grade III or IV). In these cases the initial histological findings corresponded to a grade II neoplasm; however over the recurrences it was found to be malignant [3]. To the best of our knowledge, only a few cases have been reported in the literature, which demonstrate a PXA tumor presenting with anaplastic features at initial presentation. These cases have been reported mostly in children and young adults ranging between 7–25 years [16]. Here we present a case of a primary anaplastic PXA tumor in the later age group with an unusual early recurrence pattern. We then review the literature of previously reported cases of primary anaplastic PXA tumors in adults.

2. Case description

55 years old male presented with a history of sudden onset headaches and two episodes of generalized tonic clonic seizures in 3 months. Neurological examination did not show any focal motor or sensory deficits. MRI brain showed a 2.2 × 1.3 × 1.1 cm nodular
Fig. 1. (A) MRI Brain T1 weighted showing hypointense nodular thickening in the left temporal lobe and para sylvian fissure. (B) T2 weighted image showing hyperintense lesion in the left temporal lobe. (C) T1 contrast image showing patchy enhancement in the left temporal lobe.

Fig. 2. MR spectroscopy showing high Choline/Creatine and high Choline/NAA ratios in the enhancing areas and persistent lactate peak in all enhancing areas favoring neoplastic lesion.

Fig. 3. MRI Brain showing significant overall increase in the size of tumor involving the left frontal, temporal and parietal lobes with perilesional edema and post surgical changes in T1, T1 post contrast and T2 weighted images respectively.
thickening and enhancement along left medial temporal lobe and sylvian fissure. It appeared as a multicystic lesion with peripheral enhancement and marked perilesional oedema (Fig. 1). MR Spectroscopy showed high choline/creatine and high choline/NAA ratios in the enhancing areas (Fig. 2). Patient underwent a left sided pterional craniotomy for excision of the lesion. Gross total resection of the tumor was performed. Immediate post operative MRI scan was not done due to financial constraints. Biopsy report suggested a neoplastic lesion composed of plump spindle-shaped pleomorphic cells having elongated nuclei with eosinophilic cytoplasm and other cells having bizarre pleomorphic nuclei with abundant cytoplasm. GFAP (glial fibrillary acidic protein) immune staining showed diffuse expression in tumor cells. Ki-67 staining showed a proliferative index of up to 8–10% in some areas along with the presence of increased mitoses (>5/10hpf). H & E staining also showed a few xanthomatous cells along with areas of focal necrosis. CD34 immune staining was negative excluding epithelioid cell glioblastoma (Figs. 4 and 5). Overall findings were suggestive of an anaplastic pleomorphic xanthoastrocytoma. Case was discussed in the tumor board meeting and external beam radiotherapy was advised. On follow up visit patient exhibited mild to moderate cognitive impairment, sensory dysphasia and disorientation. MRI scan was repeated 9 weeks after surgery. Repeat scan showed a significant overall increase in tumor size with both multifocal cystic and solid components involving left frontal, temporal and parietal lobes measuring approximately 9.6 × 5.1 × 5 cm clearly elicited disease progression (Fig. 3). The prognosis of the patient was discussed with family regarding further management plan and it was decided to continue radiotherapy and no surgical intervention was planned. Patient died at 16 weeks from the time of initial diagnosis.

3. Discussion

PXAs with anaplastic features is a rare tumor hence no definitive treatment guidelines have been established so far. The recent consolidated review of literature by Tmara et al. [24] in 2012 has reported 20 cases of primary anaplastic PXA in adults (18 above) so far. We report a total of 24 cases of primary APXA in adults from 1979 to 2016. We describe this case of primary anaplastic PXA in an adult male with special regard to a rapid disease progression only after a 9 weeks interval. To the best of our knowledge only one case of primary anaplastic PXA has been reported to have an earlier recurrence at 1 month (Kim et al., 2009) [12]. The average recurrence interval as per our literature review was approximately 14 months from the time of initial diagnosis. The APXA lesion was found to be mostly located in temporal and parietal lobes in most of the cases. It showed similar pattern involving the medial temporal lobe and para sylvian fissure in the aforementioned case description. Previous studies have shown presence of neuroglial tumor markers like GFAP expression with reticulin
deposition as it was seen in this case [23]. Our inference about behavior of PXA as an anaplastic tumor stems from the fact that tumor showed proliferative index of 8–10% in some areas, which along with the presence of increased mitoses (>5/10hpf) corresponded to WHO grade III classification of diffuse astrocytomas [15]. Previously reported cases of APXA also have shown similar histological characteristics (Table 2). It was seen that presence of pleomorphism was a consistent feature in majority of the cases. The APXA tissue sections show bizarre giant cells that are multinucleated or have multilobulated nuclei, with intracytoplasmatic lipid-containing vacuoles (xanthic), and are generally organized in alveolar structures, with an abundant surrounding reticulin network and perivascular lymphoid infiltrates. In contrast to benign PXA, the anaplastic variants have consistently shown high mitotic activity along with areas of focal necrosis in most of the cases. Long term control of anaplastic PXA with recurrences has been attributed to postsurgical stereotactic radiation therapy (Koga, Tomoyuki, et al.) [13]. However due to its unavailability in our facility we planned to provide external beam radiation therapy for long term palliative control of tumor. According to the current review of literature the most commonly used treatment option was surgical excision and post surgical radiotherapy. Complete surgical excision is still an effective treatment in benign PXA with excellent 5 year and 10 year survival rates; however, we found that gross total resection in APXA is still associated with frequent recurrences. Previously there was no sufficient literature supporting the role of chemotherapy in the treatment of pleomorphic xanthoastrocytomas in adults, recent studies have shown the role of BRAF V600E inhibitors in treatment of PXA tumors pertaining to the high frequency of these mutations in PXA tumors [22]. Due to the lack of BRAFV600E testing in our facility, no chemotherapy was planned for this patient. The average survival in months among the reported APXA cases was approximately 24 months from the time of initial diagnosis according to our case review (Table 1). This indicates a relatively poor prognosis in patients with anaplastic PXA tumor at the initial presentation when compared with the benign PXA tumors in adults [19].

4. Conclusion

Our review of all reported cases of APXA in adults concludes that the clinical behavior of this tumor varies considerably from its benign variant. As per this review of literature it is seen that anaplastic variant of PXA shows histological characteristics as well as clinical course comparable with Grade III astrocytomas. Early disease recurrence in anaplastic pleomorphic xanthoastrocytomas is associated with fatal outcomes.

We recommend further evaluation of PXA with anaplastic features regarding their genetic characteristics to understand the origin as well as behavior of this tumor.
Table 1
Review of previously reported primary anaplastic Pleomorphic xanthoastrocytoma cases in adults.

| Author (Date)          | Age/sex | Site                     | Treatment                               | Recurrence Interval (months) | Net survival (months) |
|-----------------------|---------|--------------------------|-----------------------------------------|------------------------------|-----------------------|
| Goldring et al. [7]   | 24/female| Temporal lobe            | Surgery + chemotherapy                  | 12 months                    | 12 months             |
| Iwaki et al. [9]      | 30/male | Parieto-occipital sulcus | Surgery + radiotherapy                  | 6 months                     | 10 months             |
| Perry et al. [21]     | 18/male | Temporal lobe            | Surgery + radiotherapy + chemotherapy   | Multiple recurrences         | 48 months             |
| Tonn et al. [23]      | 18/male | Temporal + occipital lobe| Surgery + radiotherapy + chemotherapy   | 8 months                     | 30 months             |
| Chakrabarty et al. [3]| 49/male | Temporal + occipital lobe| Surgery + radiotherapy                  | Not reported                 | Not reported          |
|                       | 40/male | Temporal lobe            | Surgery + radiotherapy                  | Not reported                 | Not reported          |
| Buccerio et al. [2]   | 65/male | Thalamic                 | Surgery + Radiotherapy                  | 22 months                    | 22 months             |
| Zhuang et al. [25]    | 53/male | Frontal lobe             | Surgery + radiotherapy + chemotherapy   | Not reported                 | 24 months             |
| Gelpi et al. [5]      | 43/female| Occipital lobe           | Surgery + Radiotherapy                  | 36 months                    | Alive                 |
| Asano et al. [11]     | 59/female| Temporal lobe            | Surgery                                 | Not reported                 | 36 months             |
| Marton et al. [16]    | 40/female| Temporal lobe            | Surgery                                 | 30 months                    | 30 months             |
| Hirose et al. [8]     | 52/male | Fronto temporal lobe      | Surgery + radiotherapy + chemotherapy   | Not reported                 | Alive                 |
|                       | 39/male | Frontal lobe             | Surgery + radiotherapy + chemotherapy   | Not reported                 | Not reported          |
|                       | 25/male | Cerebellum               | Surgery                                 | Not reported                 | Not reported          |
| Kim et al. [12]       | 45/male | Temporal lobe            | Surgery                                 | 1 month                      | 17 months             |
| Koga et al. [13]      | 47/male | Frontal lobe             | Surgery + Radiotherapy                  | Not reported                 | Not reported          |
| Frank et al. [4]      | 28/male | Temporal lobe            | Surgery + radiotherapy + chemotherapy   | 14 months                    | Not reported          |
| Lacoste-Collin et al. [14] | 45/female | Peri ventricular         | Biopsy only                             | Not reported                 | Not reported          |
| Nern, Christian et al. [18] | 57/male | Temporal lobe            | Surgery + radiotherapy + chemotherapy   | 10 months                    | 12 months             |
| Kosuke, et al. [10]   | 61/female| Pineal Gland             | Surgery + radiotherapy + chemotherapy   | Not reported                 | Alive                 |
| Montano et al. [17]   | 22/male | Parietal lobe + Temporal lobe | Surgery + radiotherapy + chemotherapy | Not reported                 | Alive                 |
| Usama et al. (Present study) | 53/male | Temporal lobe + sylvian  | Surgery + Radiotherapy                  | 2 months                     | 4 months              |

Table 2
Comparison of histological features of previously reported Anaplastic PXA tumors with the present study. (Mitosis; 0–2 cells/hpf = +; 3–5 cells/hpf = ++; 5–10 cells/hpf = +++).

| Author            | Pleomorphism | Eosinophilic hyaline globules | Nuclear inclusions | Xanthomatous cells | Mitosis | Spindle cells | Necrosis | GFAP |
|-------------------|--------------|------------------------------|--------------------|--------------------|---------|---------------|----------|------|
| Iwaki et al. [9]  | +            | +                            | +                  | +                  | +++     | +             | +        |      |
| Perry et al. [21] | +            | +                            | +                  | +                  | +       | +             | +        |      |
| Tonn et al. [23]  | +            | +                            | +                  | +                  | +       | +             | +        |      |
| Buccerio et al. [2]| +           | +                            | +                  | +                  | +       | +             | +        |      |
| Asano et al. [11] | +            | +                            | +                  | +                  | +++     | +             | +        |      |
| Marton et al. [16]| +            | +                            | +                  | +                  | +++     | +             | +        |      |
| Hirose et al. [8] | +            | +                            | +                  | +                  | +       | +             | +        |      |
| Kim et al. [12]   | +            | +                            | +                  | +                  | +       | +             | +        |      |
| Koga et al. [13]  | +            | +                            | +                  | +                  | +       | +             | +        |      |
| Frank et al. [4]  | +            | +                            | +                  | +                  | +       | +             | +        |      |
| Lacoste-Collin et al. [14] | +          | +                            | +                  | +                  | +       | +             | +        |      |
| Nern, Christian et al. [18] | +       | +                            | +                  | +                  | +       | +             | +        |      |
| Kosuke, et al. [10]| +           | +                            | +                  | +                  | +       | +             | +        |      |
| Usama et al. (Present study) | +       | +                            | +                  | +                  | +       | +             | +        |      |

Conflicts of interest
None.

Funding
None.

Ethical approval
Not required.

Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent will be made available for review by the Editor-in-Chief of this journal on request.

Author contribution
1. Saad Akhtar Khan – data analysis, interpretation, manuscript drafting.
2. Usama Khalid Choudry – study concept, study design, data collection, manuscript writing.
3. Anjali Qureshi – study concept, data analysis, proof reading.
4. Ehsan Bari – critical review of literature, data interpretation.

Guarantor

Dr. Ehsan Bari, section head, Department of Neurosurgery, Aga Khan Hospital.

Acknowledgements

1. Dr. Zeeshan ud din, Assistant professor; Department of histopathology, Aga Khan University Hospital, Karachi, Pakistan.
2. Dr. Anita George, Resident; Department of histopathology, Aga Khan University Hospital, Karachi, Pakistan.

References

[1] Asano Kenichiro, et al., A case of anaplastic pleomorphic xanthoastrocytoma presenting with tumor bleeding and cerebrospinal fluid dissemination, Brain Tumor Pathol. 23 (1) (2006) 55–63.
[2] A. Bucciero, et al., Atypical pleomorphic xanthoastrocytoma, J. Neuurosurg. Sci. 42(3) (1998) 153.
[3] A. Chakrabarty, et al., Malignant transformation in pleomorphic xanthoastrocytoma-cfa report of two cases, Br. J. Neurosurg. 13 (5) (1999) 516–519.
[4] Stephan Frank, et al., A 28-year-old man with headache, visual and aphasis speech disturbances, Brain Pathol. 19(1) (2009) 163–166.
[5] Gelpi Ellen, et al., Pleomorphic xanthoastrocytoma with anaplastic features presenting without GFAP immunoreactivity: implications for differential diagnosis, Neuropathology 25 (3) (2005) 241–246.
[6] C. Giannini, W. Paulus, D.N. Louis, et al., Pleomorphic xanthoastrocytoma, in: D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavene (Eds.), World Health Organization Classification of Tumours. WHO Classification of Tumours of the Central Nervous System, 4th ed., IARC Press, Lyon, 2007, pp. 22–24.
[7] S. Goldring, K.M. Rich, S. Picker, Experience with gliomas in patients presenting with a chronic seizure disorder, Clin. Neuropathol. 33 (1986) 15.
[8] T. Hirose, et al., Pleomorphic xanthoastrocytoma: a comparative pathological study between conventional and anaplastic types, Histopathology 52 (2) (2008) 183–193.
[9] T. Iwaki, et al., Epithelial properties of pleomorphic xanthoastrocytomas determined in ultrastructural and immunohistochemical studies, Acta Neuropathol. (Berl.) 74 (2) (1987) 142–150.
[10] Katayama Kosuke, et al., A case of pleomorphic xanthoastrocytoma with anaplastic features in the pineal gland, Brain Tumor Pathol. 30 (4) (2013) 242–246.
[11] J.J. Kepe, L.J. Rubinstein, L.F. Eng, Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis: a study of 12 cases, Cancer 44 (1979) 1839–1852.
[12] Bomi Kim, et al., Pleomorphic xanthoastrocytoma associated with long-standing Taylor-type IIIb-focal cortical dysplasia in an adult, Pathol.-Res. Prat. 205 (2) (2009) 113–117.
[13] Koga Tomoyuki, et al., Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation, Neuro-oncol. 11 (4) (2009) 446–451.
[14] Lætitia Lacoste-Collin, et al., Cerebrospinal fluid cytologic findings of a pleomorphic xanthoastrocytoma: a case report, Acta Cytol. 54 (5 Suppl) (2009) 871–874.
[15] David N. Louis, et al., The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol. (Berl.) 114 (3) (2007) 97–109, PMC. Web. 3 Nov. 2015.
[16] Marton Elisabetta, et al., Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature, J. Neurol. Sci. 252 (2) (2007) 144–153.
[17] Montano Nicola, et al., Primary multicentric anaplastic pleomorphic xanthoastrocytoma with atypical features, J. Clin. Neurosci. 20 (11) (2013) 1605–1608.
[18] Christian Nern, Jürgen Henc, Arne Fischmann, Spinal imaging in intracranial primary pleomorphic xanthoastrocytoma with anaplastic features, J. Clin. Neurosci. 19 (9) (2012) 1299–1301.
[19] Peter A. Papapoul, David A. Ramsay, Rolando F. Del Maestro, Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis, Neurosurgery 38 (4) (1996) 822–829.
[20] Perry Arie, et al., Composite pleomorphic xanthoastrocytoma and ganglioglioma: report of four cases and review of the literature, Ann. J. Surg. Pathol. 21 (7) (1997) 763–771.
[21] Schindler Genevieve, et al., Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma, Acta Neuropathol. (Berl.) 121 (3) (2011) 397–405.
[22] Jörg C. Tonn, et al., Pleomorphic xanthoastrocytoma: report of six cases with special consideration of diagnostic and therapeutic pitfalls, Surg. Neurol. 47 (2) (1997) 162–169.
[23] Tarmara M. Vu, et al., Malignant potential of pleomorphic xanthoastrocytoma, J. Clin. Neurosci. 19 (1) (2012) 12–20.
[25] Z. Zhuang, et al., Molecular genetics and proteomic analysis of synchronous malignant gliomas, Neurology 62 (12) (2004) 2316–2319.

Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.